Indication
PNH
6 clinical trials
5 products
Product
DanicopanProduct
BCX9930Clinical trial
A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Terminated, Estimated PCD: 2023-10-04
Product
PegcetacoplanClinical trial
An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
RavulizumabClinical trial
A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal HemoglobinuriaStatus: Completed, Estimated PCD: 2017-02-23
Clinical trial
A Phase 3 Open-Label Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Clinically Significant Extravascular HemolysisStatus: Not yet recruiting, Estimated PCD: 2027-01-15
Clinical trial
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH StudyStatus: Terminated, Estimated PCD: 2021-12-07
Product
Eculizumab